Antifibrotic actions of Serelaxin

New roles for an old player

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Fibrosis represents a failed wound healing response to tissue injury. It is characterized by the accumulation of excess connective tissue and is a significant cause of organ failure, morbidity, and mortality. Fibrotic disorders accompany a wide spectrum of conditions including both systemic and organ-specific diseases, for which there is currently no effective cure. Serelaxin, the recombinant form of the major stored and circulating form of human relaxin, has emerged as a pleiotropic drug with rapidly occurring antifibrotic actions. This review discusses the effectiveness of serelaxin as an antifibrotic, and how it augments the actions of several other therapeutics leading to its potential use not only as a monotherapy but also as an adjunct therapy with other antifibrotic agents.
Original languageEnglish
Pages (from-to)485-497
Number of pages13
JournalTrends in Pharmacological Sciences
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 2016

Keywords

  • collagen
  • fibrosis
  • relaxin
  • serelaxin
  • signal transduction
  • TGF-β1

Cite this

@article{3147066ff542484db5fcb1de2484f96b,
title = "Antifibrotic actions of Serelaxin: New roles for an old player",
abstract = "Fibrosis represents a failed wound healing response to tissue injury. It is characterized by the accumulation of excess connective tissue and is a significant cause of organ failure, morbidity, and mortality. Fibrotic disorders accompany a wide spectrum of conditions including both systemic and organ-specific diseases, for which there is currently no effective cure. Serelaxin, the recombinant form of the major stored and circulating form of human relaxin, has emerged as a pleiotropic drug with rapidly occurring antifibrotic actions. This review discusses the effectiveness of serelaxin as an antifibrotic, and how it augments the actions of several other therapeutics leading to its potential use not only as a monotherapy but also as an adjunct therapy with other antifibrotic agents.",
keywords = "collagen, fibrosis, relaxin, serelaxin, signal transduction, TGF-β1",
author = "Samuel, {Chrishan S.} and Summers, {Roger J.} and Hewitson, {Tim D.}",
year = "2016",
month = "6",
doi = "10.1016/j.tips.2016.02.007",
language = "English",
volume = "37",
pages = "485--497",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier",
number = "6",

}

Antifibrotic actions of Serelaxin : New roles for an old player. / Samuel, Chrishan S.; Summers, Roger J.; Hewitson, Tim D.

In: Trends in Pharmacological Sciences, Vol. 37, No. 6, 06.2016, p. 485-497.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Antifibrotic actions of Serelaxin

T2 - New roles for an old player

AU - Samuel, Chrishan S.

AU - Summers, Roger J.

AU - Hewitson, Tim D.

PY - 2016/6

Y1 - 2016/6

N2 - Fibrosis represents a failed wound healing response to tissue injury. It is characterized by the accumulation of excess connective tissue and is a significant cause of organ failure, morbidity, and mortality. Fibrotic disorders accompany a wide spectrum of conditions including both systemic and organ-specific diseases, for which there is currently no effective cure. Serelaxin, the recombinant form of the major stored and circulating form of human relaxin, has emerged as a pleiotropic drug with rapidly occurring antifibrotic actions. This review discusses the effectiveness of serelaxin as an antifibrotic, and how it augments the actions of several other therapeutics leading to its potential use not only as a monotherapy but also as an adjunct therapy with other antifibrotic agents.

AB - Fibrosis represents a failed wound healing response to tissue injury. It is characterized by the accumulation of excess connective tissue and is a significant cause of organ failure, morbidity, and mortality. Fibrotic disorders accompany a wide spectrum of conditions including both systemic and organ-specific diseases, for which there is currently no effective cure. Serelaxin, the recombinant form of the major stored and circulating form of human relaxin, has emerged as a pleiotropic drug with rapidly occurring antifibrotic actions. This review discusses the effectiveness of serelaxin as an antifibrotic, and how it augments the actions of several other therapeutics leading to its potential use not only as a monotherapy but also as an adjunct therapy with other antifibrotic agents.

KW - collagen

KW - fibrosis

KW - relaxin

KW - serelaxin

KW - signal transduction

KW - TGF-β1

UR - http://www.ncbi.nlm.nih.gov/pubmed/26996448

U2 - 10.1016/j.tips.2016.02.007

DO - 10.1016/j.tips.2016.02.007

M3 - Review Article

VL - 37

SP - 485

EP - 497

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 6

ER -